Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Current Assets (2019 - 2025)

Historic Current Assets for aTYR PHARMA (ATYR) over the last 7 years, with Q3 2025 value amounting to $93.0 million.

  • aTYR PHARMA's Current Assets rose 2187.85% to $93.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $93.0 million, marking a year-over-year increase of 2187.85%. This contributed to the annual value of $82.0 million for FY2024, which is 2042.68% down from last year.
  • According to the latest figures from Q3 2025, aTYR PHARMA's Current Assets is $93.0 million, which was up 2187.85% from $87.5 million recorded in Q2 2025.
  • aTYR PHARMA's Current Assets' 5-year high stood at $121.6 million during Q3 2021, with a 5-year trough of $46.4 million in Q2 2021.
  • For the 5-year period, aTYR PHARMA's Current Assets averaged around $92.1 million, with its median value being $93.0 million (2025).
  • As far as peak fluctuations go, aTYR PHARMA's Current Assets skyrocketed by 21963.36% in 2021, and later plummeted by 3038.45% in 2022.
  • Quarter analysis of 5 years shows aTYR PHARMA's Current Assets stood at $113.6 million in 2021, then decreased by 28.79% to $80.9 million in 2022, then rose by 27.35% to $103.0 million in 2023, then fell by 20.43% to $82.0 million in 2024, then grew by 13.5% to $93.0 million in 2025.
  • Its Current Assets was $93.0 million in Q3 2025, compared to $87.5 million in Q2 2025 and $83.3 million in Q1 2025.